Answers are grounded in this paper and cite their sources.
Therapeutic modulation of interleukin-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to 1 year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen.
No takes yet. Share an insight, caveat, or question.
Mastorino et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: